Financials in USD. Standardized financial statements.
A compact view of how Proto Script Pharmaceutical Corp. turns revenue into operating income and net income.
| Metric | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|
| Revenue? | $788,960 | $881,442 | $0 | $0 | $0 |
| Revenue Growth? | -10.5% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $224,490 | $187,147 | $0 | $0 | $0 |
| Gross Profit? | $564,470 | $694,295 | $0 | $0 | $0 |
| Gross Margin? | +71.5% | +78.8% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $862,553 | $840,981 | $38,259 | $32,423 | $32,847 |
| Operating Income? | -$298,083 | -$146,686 | -$38,259 | -$32,423 | -$32,847 |
| EBITDA? | -$292,961 | -$70,840 | -$45,180 | -$38,259 | -$32,423 |
| Income Before Tax | -$7.18M | -$145,249 | -$38,259 | -$32,423 | -$32,847 |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$7.18M | -$145,249 | -$38,259 | -$32,423 | -$32,847 |
| EPS? | $-0.08 | $-0.00 | $-0.00 | $-0.00 | $-0.00 |
| Diluted EPS? | $-0.08 | $-0.00 | $-0.00 | $-0.00 | $-0.00 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality